ARCA biopharma, Inc. (ABIO) saw its loss widen to $4.34 million, or $0.48 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $3.65 million, or $0.40 a share.

The company has not recorded any revenues for the current as well as previous quarter.

Operating loss for the quarter was $4.38 million, compared with an operating loss of $3.67 million in the previous year period.

"We've made great progress so far this year, recently achieving enrollment of the 200th patient in the GENETIC-AF clinical trial. The strategies we’ve implemented have increased the rate of patient enrollment. We'd like to thank the investigators and the study patients, whose support and enthusiasm suggests a high unmet medical need for this patient population and potentially a substantial market opportunity if Gencaro is approved," commented Dr. Michael Bristow, ARCA's president and chief executive officer. "We are focused on the upcoming DSMB interim efficacy analysis that will determine the next steps for this adaptive, seamless design trial ��" transitioning to Phase 3 and enrolling an additional 370 patients; completing Phase 2B with 250 patients; or, stopping immediately for futility. We expect the outcome of this interim efficacy analysis in September 2017."